ProCE Banner Activity

Randomized Phase II OPTIC Trial of 3 Starting Doses of Ponatinib in Patients With CP-CML: Analysis by Mutation Status and Line of Therapy

Slideset Download
Conference Coverage
In an interim analysis of the randomized phase II OPTIC trial, the maximum benefit:risk ratio with ponatinib was observed with 45-mg starting dose in previously treated CP-CML regardless of mutation status or number of previous TKIs.

Released: December 10, 2020

Expiration: December 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology